The use of tadalafil in the treatment of lower urinary tract symptoms among men suffering from benign prostatic hyperplasia, on the example of the population of the Greater Poland province

Abstract The purpose of this study was to evaluate the efficacy of tadalafil 5 mg in patients over 65 years old previously treated for benign prostatic hyperplasia (BPH) with tamsulosin 0.4 mg in the Greater Poland region. A total of 126 patients who had not previously used tadalafil or other 5-phosphodiesterase inhibitors were initially analyzed. They were assessed using the International Prostatic Symptom Scale (IPSS) and the International Erectile Index Scale (IIEF-5), with mean scores of 25 points and 16 points, respectively. After excluding patients with contraindications, 81 men met the medical criteria for tadalafil inclusion. After three months of therapy, patients were reassessed on the IPSS and IIEF-5 scales, with mean scores of 21 points and 19 points, respectively. The results of the study suggest that tadalafil 5 mg is effective in improving both lower urinary tract symptoms associated with BPH and erectile function in older patients.